New vaccine-like shot aims to stop breast cancer recurrence in high-risk patients
Disease control
Recruiting now
This phase 3 trial tests an immunotherapy called GLSI-100 in 750 people with HER2-positive breast cancer who are at high risk of their cancer returning after standard treatment. Participants receive a series of injections over a year to help their immune system target and destroy…
Phase: PHASE3 • Sponsor: Greenwich LifeSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC